News & Updates
Excerpt from the Press Release: South San Francisco, CA — April 24, 2025 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).The trial met its primary endpoint,…
Read MoreExcerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months…
Read MoreA vaccine under development at UB has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. Excerpt from the Press Release: The work, detailed in a study published April 17 in the journal Cell Biomaterials, focuses on the H5N1 variant known as 2.3.4.4b, which has caused widespread outbreaks…
Read MoreI Peace, in Cooperation with SBI Holdings, Unveils Next-Gen Cell Mass-Manufacturing System “EGG” at SBI Holdings Inc. booth in the Osaka Healthcare Pavilion “Nest for Reborn” at the 2025 World Expo, Osaka Excerpt from the Press Release: PALO ALTO, Calif. , April 24, 2025 /PRNewswire/ — I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived…
Read MoreExcerpt from the Press Release: FOSTER CITY, Calif. and DURHAM, N.C., April 24, 2025 /PRNewswire/ — 1Cell.Ai, a global leader in single cell precision diagnostics, has joined forces with BioSkryb Genomics, a pioneer in single cell multi-omics, to co-develop and commercialize next-generation single cell multi-omic solutions. This collaboration will empower researchers and clinicians to detect…
Read More84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously Excerpt from the Press Release: NEWARK,…
Read MoreExcerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that BriaPro is developing novel,…
Read MoreExcerpt from the Press Release: PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, following the formation of its proposed joint venture with IPMC Company,…
Read MoreTrialStat will be showcasing our cutting-edge EDC Platform with integrated Medical Imaging Platform at the COG New England Meeting in Burlington, Massachusetts on April 28th – 30th. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing clinical research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read MoreThe Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery. Its aim is to create a pipeline of validated cancer targets and First-in-Class (FiC) or Best-in-Class (BiC), novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?